Duchenne muscular dystrophy: CRISPR/Cas9 treatment (Q40880967)

24 September 2017

Duchenne muscular dystrophy: CRISPR/Cas9 treatment (English)

1 reference

Duchenne muscular dystrophy

24 September 2017

0 references

1 reference

0 references

Jerry R Mendell

1

1 reference

24 September 2017

Louise R Rodino-Klapac

series ordinal

2

1 reference

24 September 2017

1 March 2016

1 reference

24 September 2017

1 reference

24 September 2017

26

1 reference

24 September 2017

5

1 reference

24 September 2017

513-514

1 reference

In vivo gene editing in dystrophic mouse muscle and muscle stem cells

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Corticosteroids in Duchenne muscular dystrophy: major variations in practice

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Dystrophin immunity in Duchenne's muscular dystrophy.

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856761

Evidence-based path to newborn screening for Duchenne muscular dystrophy

19 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26926391

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/CR.2016.28

1 reference

Dimensions Publication ID

24 September 2017

0 references

1 reference

24 September 2017

PubMed publication ID

26926391

1 reference